Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial.

JAMA Neurol · 2023 · PMC10628834 · PMID 37930669

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Brexpiprazole, 2 or 3 mg, showed nominally significant greater improvement vs placebo on all other secondary end points (CMAI factor scores, CGI-I score, CMAI/CGI-I response rates) at week 12 ( Table 2 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.